Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 351

1.

Comparisons of Human Immunodeficiency Virus Type 1 Envelope Variants in Blood and Genital Fluids near the Time of Male-to-Female Transmission.

Williams-Wietzikoski CA, Campbell MS, Payant R, Lam A, Zhao H, Huang H, Wald A, Stevens W, Gray G, Farquhar C, Rees H, Celum C, Mullins JI, Lingappa JR, Frenkel LM.

J Virol. 2019 Jun 14;93(13). pii: e01769-18. doi: 10.1128/JVI.01769-18. Print 2019 Jul 1.

PMID:
30996101
2.

Phylogenetic Analyses Comparing HIV Sequences from Plasma at Virologic Failure to Cervix Versus Blood Sequences from Antecedent Antiretroviral Therapy Suppression.

Bull ME, McKernan JL, Styrchak S, Kraft K, Hitti J, Cohn SE, Tapia K, Deng W, Holte S, Mullins JI, Coombs RW, Frenkel LM.

AIDS Res Hum Retroviruses. 2019 Jun;35(6):557-566. doi: 10.1089/AID.2018.0211. Epub 2019 Apr 30.

PMID:
30892052
3.

Correction: Whole genome sequencing of extreme phenotypes identifies variants in CD101 and UBE2V1 associated with increased risk of sexually acquired HIV-1.

Mackelprang RD, Bamshad MJ, Chong JX, Hou X, Buckingham KJ, Shively K, deBruyn G, Mugo NR, Mullins JI, McElrath MJ, Baeten JM, Celum C, Emond MJ, Lingappa JR; Partners in Prevention HSV/HIV Transmission Study and the Partners PrEP Study Teams.

PLoS Pathog. 2019 Feb 11;15(2):e1007588. doi: 10.1371/journal.ppat.1007588. eCollection 2019 Feb.

4.

Mucosal T Helper 17 and T Regulatory Cell Homeostasis Correlate with Acute Simian Immunodeficiency Virus Viremia and Responsiveness to Antiretroviral Therapy in Macaques.

O'Connor MA, Munson PV, Tunggal HC, Hajari N, Lewis TB, Bratt D, Moats C, Smedley J, Bagley KC, Mullins JI, Fuller DH.

AIDS Res Hum Retroviruses. 2019 Mar;35(3):295-305. doi: 10.1089/AID.2018.0184. Epub 2019 Jan 2.

PMID:
30398361
5.

ISDB: a database toolkit for storing and analyzing viral integration site data.

Sibley TR, Silberman EJ, Mullins JI.

Bioinformatics. 2019 Mar 15;35(6):1073-1075. doi: 10.1093/bioinformatics/bty712.

PMID:
30165425
6.

Gag and env conserved element CE DNA vaccines elicit broad cytotoxic T cell responses targeting subdominant epitopes of HIV and SIV Able to recognize virus-infected cells in macaques.

Hu X, Lu Z, Valentin A, Rosati M, Broderick KE, Sardesai NY, Marx PA, Mullins JI, Pavlakis GN, Felber BK.

Hum Vaccin Immunother. 2018;14(9):2163-2177. doi: 10.1080/21645515.2018.1489949. Epub 2018 Jul 12.

7.

DNA Vaccine-Induced Long-Lasting Cytotoxic T Cells Targeting Conserved Elements of Human Immunodeficiency Virus Gag Are Boosted Upon DNA or Recombinant Modified Vaccinia Ankara Vaccination.

Hu X, Valentin A, Cai Y, Dayton F, Rosati M, Ramírez-Salazar EG, Kulkarni V, Broderick KE, Sardesai NY, Wyatt LS, Earl PL, Moss B, Mullins JI, Pavlakis GN, Felber BK.

Hum Gene Ther. 2018 Sep;29(9):1029-1043. doi: 10.1089/hum.2018.065. Epub 2018 Jun 21.

8.

No Time to Delay! Fiebig Stages and Referral in Acute HIV infection: Seattle Primary Infection Program Experience.

Stekler JD, Tapia K, Maenza J, Stevens CE, Ure GA, O'Neal JD, Lane A, Mullins JI, Coombs RW, Holte S, Collier AC.

AIDS Res Hum Retroviruses. 2018 Aug;34(8):657-666. doi: 10.1089/AID.2017.0276. Epub 2018 Jun 13.

9.

Therapeutic conserved elements (CE) DNA vaccine induces strong T-cell responses against highly conserved viral sequences during simian-human immunodeficiency virus infection.

Munson P, Liu Y, Bratt D, Fuller JT, Hu X, Pavlakis GN, Felber BK, Mullins JI, Fuller DH.

Hum Vaccin Immunother. 2018 Jul 3;14(7):1820-1831. doi: 10.1080/21645515.2018.1448328. Epub 2018 Apr 12.

10.

Transmission of HIV-1 drug resistance mutations within partner-pairs: A cross-sectional study of a primary HIV infection cohort.

Stekler JD, Milne R, Payant R, Beck I, Herbeck J, Maust B, Deng W, Tapia K, Holte S, Maenza J, Stevens CE, Mullins JI, Collier AC, Frenkel LM.

PLoS Med. 2018 Mar 27;15(3):e1002537. doi: 10.1371/journal.pmed.1002537. eCollection 2018 Mar.

11.

HIV population-level adaptation can rapidly diminish the impact of a partially effective vaccine.

Herbeck JT, Peebles K, Edlefsen PT, Rolland M, Murphy JT, Gottlieb GS, Abernethy N, Mullins JI, Mittler JE, Goodreau SM.

Vaccine. 2018 Jan 25;36(4):514-520. doi: 10.1016/j.vaccine.2017.12.004. Epub 2017 Dec 11.

12.

Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120.

deCamp AC, Rolland M, Edlefsen PT, Sanders-Buell E, Hall B, Magaret CA, Fiore-Gartland AJ, Juraska M, Carpp LN, Karuna ST, Bose M, LePore S, Miller S, O'Sullivan A, Poltavee K, Bai H, Dommaraju K, Zhao H, Wong K, Chen L, Ahmed H, Goodman D, Tay MZ, Gottardo R, Koup RA, Bailer R, Mascola JR, Graham BS, Roederer M, O'Connell RJ, Michael NL, Robb ML, Adams E, D'Souza P, Kublin J, Corey L, Geraghty DE, Frahm N, Tomaras GD, McElrath MJ, Frenkel L, Styrchak S, Tovanabutra S, Sobieszczyk ME, Hammer SM, Kim JH, Mullins JI, Gilbert PB.

PLoS One. 2017 Nov 17;12(11):e0185959. doi: 10.1371/journal.pone.0185959. eCollection 2017.

13.

Whole genome sequencing of extreme phenotypes identifies variants in CD101 and UBE2V1 associated with increased risk of sexually acquired HIV-1.

Mackelprang RD, Bamshad MJ, Chong JX, Hou X, Buckingham KJ, Shively K, deBruyn G, Mugo NR, Mullins JI, McElrath MJ, Baeten JM, Celum C, Emond MJ, Lingappa JR; Partners in Prevention HSV/HIV Transmission Study and the Partners PrEP Study Teams.

PLoS Pathog. 2017 Nov 6;13(11):e1006703. doi: 10.1371/journal.ppat.1006703. eCollection 2017 Nov. Erratum in: PLoS Pathog. 2019 Feb 11;15(2):e1007588.

14.

Patterns and rates of viral evolution in HIV-1 subtype B infected females and males.

Dapp MJ, Kober KM, Chen L, Westfall DH, Wong K, Zhao H, Hall BM, Deng W, Sibley T, Ghorai S, Kim K, Chen N, McHugh S, Au L, Cohen M, Anastos K, Mullins JI.

PLoS One. 2017 Oct 18;12(10):e0182443. doi: 10.1371/journal.pone.0182443. eCollection 2017.

15.

HIV Env conserved element DNA vaccine alters immunodominance in macaques.

Hu X, Valentin A, Rosati M, Manocheewa S, Alicea C, Chowdhury B, Bear J, Broderick KE, Sardesai NY, Gall SL, Mullins JI, Pavlakis GN, Felber BK.

Hum Vaccin Immunother. 2017 Dec 2;13(12):2859-2871. doi: 10.1080/21645515.2017.1339852. Epub 2017 Jul 5.

16.

Clonal Expansion of Human Immunodeficiency Virus-Infected Cells and Human Immunodeficiency Virus Persistence During Antiretroviral Therapy.

Mullins JI, Frenkel LM.

J Infect Dis. 2017 Mar 15;215(suppl_3):S119-S127. doi: 10.1093/infdis/jiw636. Review.

17.

Breast milk and in utero transmission of HIV-1 select for envelope variants with unique molecular signatures.

Nakamura KJ, Heath L, Sobrera ER, Wilkinson TA, Semrau K, Kankasa C, Tobin NH, Webb NE, Lee B, Thea DM, Kuhn L, Mullins JI, Aldrovandi GM.

Retrovirology. 2017 Jan 26;14(1):6. doi: 10.1186/s12977-017-0331-z.

18.

HIV Transmission During Condomless Sex With a Seropositive Partner With Suppressed Infection.

Goldman JD, Frenkel LM, Mullins JI.

JAMA. 2016 Nov 15;316(19):2044-2045. doi: 10.1001/jama.2016.16030. No abstract available.

PMID:
27838715
19.

A study of vaccine-induced immune pressure on breakthrough infections in the Phambili phase 2b HIV-1 vaccine efficacy trial.

Hertz T, Logan MG, Rolland M, Magaret CA, Rademeyer C, Fiore-Gartland A, Edlefsen PT, DeCamp A, Ahmed H, Ngandu N, Larsen BB, Frahm N, Marais J, Thebus R, Geraghty D, Hural J, Corey L, Kublin J, Gray G, McElrath MJ, Mullins JI, Gilbert PB, Williamson C.

Vaccine. 2016 Nov 11;34(47):5792-5801. doi: 10.1016/j.vaccine.2016.09.054. Epub 2016 Oct 15.

20.

DNA Prime-Boost Vaccine Regimen To Increase Breadth, Magnitude, and Cytotoxicity of the Cellular Immune Responses to Subdominant Gag Epitopes of Simian Immunodeficiency Virus and HIV.

Hu X, Valentin A, Dayton F, Kulkarni V, Alicea C, Rosati M, Chowdhury B, Gautam R, Broderick KE, Sardesai NY, Martin MA, Mullins JI, Pavlakis GN, Felber BK.

J Immunol. 2016 Nov 15;197(10):3999-4013. Epub 2016 Oct 12.

21.

High-Sequence Diversity and Rapid Virus Turnover Contribute to Higher Rates of Coreceptor Switching in Treatment-Experienced Subjects with HIV-1 Viremia.

Nedellec R, Herbeck JT, Hunt PW, Deeks SG, Mullins JI, Anton ED, Reeves JD, Mosier DE.

AIDS Res Hum Retroviruses. 2017 Mar;33(3):234-245. doi: 10.1089/AID.2016.0153. Epub 2016 Oct 12.

22.

Erratum for Smith et al., Effective Cytotoxic T Lymphocyte Targeting of Persistent HIV-1 during Antiretroviral Therapy Requires Priming of Naive CD8+ T Cells.

Smith KN, Mailliard RB, Piazza PA, Fischer W, Korber BT, Fecek RJ, Ratner D, Gupta P, Mullins JI, Rinaldo CR.

MBio. 2016 Jul 12;7(4). pii: e01012-16. doi: 10.1128/mBio.01012-16. No abstract available.

23.

Effective Cytotoxic T Lymphocyte Targeting of Persistent HIV-1 during Antiretroviral Therapy Requires Priming of Naive CD8+ T Cells.

Smith KN, Mailliard RB, Piazza PA, Fischer W, Korber BT, Fecek RJ, Ratner D, Gupta P, Mullins JI, Rinaldo CR.

MBio. 2016 May 31;7(3). pii: e00473-16. doi: 10.1128/mBio.00473-16. Erratum in: MBio. 2016;7(4). pii: e01012-16. doi: 10.1128/mBio.01012-16.

24.

A Pilot Study of Raltegravir Plus Combination Antiretroviral Therapy in Early Human Immunodeficiency Virus Infection: Challenges and Lessons Learned.

Collier AC, Chun TW, Maenza J, Coombs RW, Tapia K, Chang M, Stevens CE, Justement JS, Murray D, Stekler JD, Mullins JI, Holte SE.

Biores Open Access. 2016 Jan 1;5(1):15-21. doi: 10.1089/biores.2015.0038. eCollection 2016.

25.

Composite Sequence-Structure Stability Models as Screening Tools for Identifying Vulnerable Targets for HIV Drug and Vaccine Development.

Manocheewa S, Mittler JE, Samudrala R, Mullins JI.

Viruses. 2015 Nov 4;7(11):5718-35. doi: 10.3390/v7112901.

26.

Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load.

McLaren PJ, Coulonges C, Bartha I, Lenz TL, Deutsch AJ, Bashirova A, Buchbinder S, Carrington MN, Cossarizza A, Dalmau J, De Luca A, Goedert JJ, Gurdasani D, Haas DW, Herbeck JT, Johnson EO, Kirk GD, Lambotte O, Luo M, Mallal S, van Manen D, Martinez-Picado J, Meyer L, Miro JM, Mullins JI, Obel N, Poli G, Sandhu MS, Schuitemaker H, Shea PR, Theodorou I, Walker BD, Weintrob AC, Winkler CA, Wolinsky SM, Raychaudhuri S, Goldstein DB, Telenti A, de Bakker PI, Zagury JF, Fellay J.

Proc Natl Acad Sci U S A. 2015 Nov 24;112(47):14658-63. doi: 10.1073/pnas.1514867112. Epub 2015 Nov 9.

27.

Lack of viral control and development of combination antiretroviral therapy escape mutations in macaques after bone marrow transplantation.

Peterson CW, Haworth KG, Polacino P, Huang ML, Sykes C, Obenza WM, Repetto AC, Kashuba A, Bumgarner R, DeRosa SC, Woolfrey AE, Jerome KR, Mullins JI, Hu SL, Kiem HP.

AIDS. 2015 Aug 24;29(13):1597-606. doi: 10.1097/QAD.0000000000000702.

28.

HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders.

Janes H, Herbeck JT, Tovanabutra S, Thomas R, Frahm N, Duerr A, Hural J, Corey L, Self SG, Buchbinder SP, McElrath MJ, O'Connell RJ, Paris RM, Rerks-Ngarm S, Nitayaphan S, Pitisuttihum P, Kaewkungwal J, Robb ML, Michael NL, Mullins JI, Kim JH, Gilbert PB, Rolland M.

Nat Med. 2015 Oct;21(10):1139-41. doi: 10.1038/nm.3932. Epub 2015 Aug 31.

29.

Comparison of Major and Minor Viral SNPs Identified through Single Template Sequencing and Pyrosequencing in Acute HIV-1 Infection.

Iyer S, Casey E, Bouzek H, Kim M, Deng W, Larsen BB, Zhao H, Bumgarner RE, Rolland M, Mullins JI.

PLoS One. 2015 Aug 28;10(8):e0135903. doi: 10.1371/journal.pone.0135903. eCollection 2015.

30.

Resistance detected by pyrosequencing following zidovudine monotherapy for prevention of HIV-1 mother-to-child-transmission.

Olson SC, Ngo-Giang-Huong N, Beck I, Deng W, Britto P, Shapiro DE, Bumgarner RE, Mullins JI, Van Dyke RB, Jourdain G, Frenkel LM.

AIDS. 2015 Jul 31;29(12):1467-71. doi: 10.1097/QAD.0000000000000737.

31.

Fitness-Balanced Escape Determines Resolution of Dynamic Founder Virus Escape Processes in HIV-1 Infection.

Sunshine JE, Larsen BB, Maust B, Casey E, Deng W, Chen L, Westfall DH, Kim M, Zhao H, Ghorai S, Lanxon-Cookson E, Rolland M, Collier AC, Maenza J, Mullins JI, Frahm N.

J Virol. 2015 Oct;89(20):10303-18. doi: 10.1128/JVI.01876-15. Epub 2015 Jul 29.

32.

Pairwise growth competition assay for determining the replication fitness of human immunodeficiency viruses.

Manocheewa S, Lanxon-Cookson EC, Liu Y, Swain JV, McClure J, Rao U, Maust B, Deng W, Sunshine JE, Kim M, Rolland M, Mullins JI.

J Vis Exp. 2015 May 4;(99):e52610. doi: 10.3791/52610.

33.

How often does treatment of primary HIV lead to post-treatment control?

Maenza J, Tapia K, Holte S, Stekler JD, Stevens CE, Mullins JI, Collier AC.

Antivir Ther. 2015;20(8):855-63. doi: 10.3851/IMP2963. Epub 2015 Apr 23.

34.

A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques.

Mothe B, Hu X, Llano A, Rosati M, Olvera A, Kulkarni V, Valentin A, Alicea C, Pilkington GR, Sardesai NY, Rocafort M, Crespo M, Carrillo J, Marco A, Mullins JI, Dorrell L, Hanke T, Clotet B, Pavlakis GN, Felber BK, Brander C.

J Transl Med. 2015 Feb 15;13:60. doi: 10.1186/s12967-015-0392-5.

35.

In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2.

Smith RA, Raugi DN, Pan C, Sow PS, Seydi M, Mullins JI, Gottlieb GS; University of Washington-Dakar HIV-2 Study Group.

Retrovirology. 2015 Feb 5;12:10. doi: 10.1186/s12977-015-0146-8.

36.

p21(WAF1/CIP1) RNA expression in highly HIV-1 exposed, uninfected individuals.

Herbeck J, Ghorai S, Chen L, Rinaldo CR, Margolick JB, Detels R, Jacobson L, Wolinsky S, Mullins JI.

PLoS One. 2015 Mar 6;10(3):e0119218. doi: 10.1371/journal.pone.0119218. eCollection 2015.

37.

Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial.

Edlefsen PT, Rolland M, Hertz T, Tovanabutra S, Gartland AJ, deCamp AC, Magaret CA, Ahmed H, Gottardo R, Juraska M, McCoy C, Larsen BB, Sanders-Buell E, Carrico C, Menis S, Kijak GH, Bose M; RV144 Sequencing Team, Arroyo MA, O'Connell RJ, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Rerks-Ngarm S, Robb ML, Kirys T, Georgiev IS, Kwong PD, Scheffler K, Pond SL, Carlson JM, Michael NL, Schief WR, Mullins JI, Kim JH, Gilbert PB.

PLoS Comput Biol. 2015 Feb 3;11(2):e1003973. doi: 10.1371/journal.pcbi.1003973. eCollection 2015 Feb. Erratum in: PLoS Comput Biol. 2016 Jan;12(1):e1004733.

38.

Performance of commonly used genotypic assays and comparison with phenotypic assays of HIV-1 coreceptor tropism in acutely HIV-1-infected patients.

Ceresola ER, Nozza S, Sampaolo M, Pignataro AR, Saita D, Ferrarese R, Ripa M, Deng W, Mullins JI, Boeri E, Tambussi G, Toniolo A, Lazzarin A, Clementi M, Canducci F.

J Antimicrob Chemother. 2015 May;70(5):1391-5. doi: 10.1093/jac/dku573. Epub 2015 Jan 20.

39.

Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses.

Zolla-Pazner S, Edlefsen PT, Rolland M, Kong XP, deCamp A, Gottardo R, Williams C, Tovanabutra S, Sharpe-Cohen S, Mullins JI, deSouza MS, Karasavvas N, Nitayaphan S, Rerks-Ngarm S, Pitisuttihum P, Kaewkungwal J, O'Connell RJ, Robb ML, Michael NL, Kim JH, Gilbert P.

EBioMedicine. 2014 Nov 1;1(1):37-45.

40.

Spontaneous control of HIV-1 viremia in a subject with protective HLA-B plus HLA-C alleles and HLA-C associated single nucleotide polymorphisms.

Moroni M, Ghezzi S, Baroli P, Heltai S, De Battista D, Pensieroso S, Cavarelli M, Dispinseri S, Vanni I, Pastori C, Zerbi P, Tosoni A, Vicenzi E, Nebuloni M, Wong K, Zhao H, McHugh S, Poli G, Lopalco L, Scarlatti G, Biassoni R, Mullins JI, Malnati MS, Alfano M.

J Transl Med. 2014 Dec 5;12:335. doi: 10.1186/s12967-014-0335-6.

41.

Host genetic and viral determinants of HIV-1 RNA set point among HIV-1 seroconverters from sub-saharan Africa.

Mackelprang RD, Carrington M, Thomas KK, Hughes JP, Baeten JM, Wald A, Farquhar C, Fife K, Campbell MS, Kapiga S, Gao X, Mullins JI, Lingappa JR.

J Virol. 2015 Feb;89(4):2104-11. doi: 10.1128/JVI.01573-14. Epub 2014 Dec 3.

42.

CD8 and CD4 epitope predictions in RV144: no strong evidence of a T-cell driven sieve effect in HIV-1 breakthrough sequences from trial participants.

Dommaraju K, Kijak G, Carlson JM, Larsen BB, Tovanabutra S, Geraghty DE, Deng W, Maust BS, Edlefsen PT, Sanders-Buell E, Ratto-Kim S, deSouza MS, Rerks-Ngarm S, Nitayaphan S, Pitisuttihum P, Kaewkungwal J, O'Connell RJ, Robb ML, Michael NL, Mullins JI, Kim JH, Rolland M.

PLoS One. 2014 Oct 28;9(10):e111334. doi: 10.1371/journal.pone.0111334. eCollection 2014.

43.

HIV-1 conserved elements p24CE DNA vaccine induces humoral immune responses with broad epitope recognition in macaques.

Kulkarni V, Valentin A, Rosati M, Rolland M, Mullins JI, Pavlakis GN, Felber BK.

PLoS One. 2014 Oct 22;9(10):e111085. doi: 10.1371/journal.pone.0111085. eCollection 2014.

44.

HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection.

Wagner TA, McLaughlin S, Garg K, Cheung CY, Larsen BB, Styrchak S, Huang HC, Edlefsen PT, Mullins JI, Frenkel LM.

Science. 2014 Aug 1;345(6196):570-3. doi: 10.1126/science.1256304. Epub 2014 Jul 10.

45.

An HIV epidemic model based on viral load dynamics: value in assessing empirical trends in HIV virulence and community viral load.

Herbeck JT, Mittler JE, Gottlieb GS, Mullins JI.

PLoS Comput Biol. 2014 Jun 19;10(6):e1003673. doi: 10.1371/journal.pcbi.1003673. eCollection 2014 Jun.

46.

Dendritic cells restore CD8+ T cell reactivity to autologous HIV-1.

Smith KN, Mailliard RB, Larsen BB, Wong K, Gupta P, Mullins JI, Rinaldo CR.

J Virol. 2014 Sep 1;88(17):9976-90. doi: 10.1128/JVI.01275-14. Epub 2014 Jun 18.

47.

HIV-1 superinfection with a triple-class drug-resistant strain in a patient successfully controlled with antiretroviral treatment.

Castro E, Zhao H, Cavassini M, Mullins JI, Pantaleo G, Bart PA.

AIDS. 2014 Jul 31;28(12):1840-4. doi: 10.1097/QAD.0000000000000342.

PMID:
24911350
48.

Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007-2013.

Stekler JD, McKernan J, Milne R, Tapia KA, Mykhalchenko K, Holte S, Maenza J, Stevens CE, Buskin SE, Mullins JI, Frenkel LM, Collier AC.

Antivir Ther. 2015;20(1):77-80. doi: 10.3851/IMP2780. Epub 2014 May 15.

49.

Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial.

Gartland AJ, Li S, McNevin J, Tomaras GD, Gottardo R, Janes H, Fong Y, Morris D, Geraghty DE, Kijak GH, Edlefsen PT, Frahm N, Larsen BB, Tovanabutra S, Sanders-Buell E, deCamp AC, Magaret CA, Ahmed H, Goodridge JP, Chen L, Konopa P, Nariya S, Stoddard JN, Wong K, Zhao H, Deng W, Maust BS, Bose M, Howell S, Bates A, Lazzaro M, O'Sullivan A, Lei E, Bradfield A, Ibitamuno G, Assawadarachai V, O'Connell RJ, deSouza MS, Nitayaphan S, Rerks-Ngarm S, Robb ML, Sidney J, Sette A, Zolla-Pazner S, Montefiori D, McElrath MJ, Mullins JI, Kim JH, Gilbert PB, Hertz T.

J Virol. 2014 Aug;88(15):8242-55. doi: 10.1128/JVI.01164-14. Epub 2014 May 14.

50.

Validation of an oligonucleotide ligation assay for quantification of human immunodeficiency virus type 1 drug-resistant mutants by use of massively parallel sequencing.

Beck IA, Deng W, Payant R, Hall R, Bumgarner RE, Mullins JI, Frenkel LM.

J Clin Microbiol. 2014 Jul;52(7):2320-7. doi: 10.1128/JCM.00306-14. Epub 2014 Apr 16.

Supplemental Content

Loading ...
Support Center